CTP-543
DrugTwice daily dosing
NCT Number: NCT03898479
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
This study is active but is not currently recruiting participants.
Notify Me18 year–65 year
All sexes
Interventional
Phase 2 / Phase 3
Dermatology Research Institute, Calgary, Alberta, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Twice daily dosing
Time frame: 332 weeks
Time frame: 332 weeks
Sun Pharmaceutical Industries, Inc.
Industry
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07023302
Alopecia, Alopecia Areata
Nagoya, Aichi-ken, Japan
View Trial DetailsNCT06340360
Alopecia, Alopecia Areata
Northridge, California, United States
View Trial DetailsNCT06602232
Alopecia, Alopecia Areata
Northridge, California, United States
View Trial DetailsNCT07226531
Alopecia, Alopecia Areata
New York, United States
View Trial Details